Targeting adenocarcinoma and enzalutamide‑resistant prostate cancer using the novel anti‑androgen inhibitor ADA‑308
Oncology Reports · 2024
DOI: 10.3892/or.2024.8791 ↗Kurz gefasst
Fachartikel in der Zeitschrift Oncology Reports, 2024. Verfasst von Shaghayegh Nouruzi und 7 weiteren Autor:innen. Beteiligte Einrichtung: Vancouver Prostate Centre, Vancouver, BC V6H 3Z6, Canada. Hauptthemen laut MEDLINE: Phenylthiohydantoin, Nitriles, Benzamides, Drug Resistance, Neoplasm. Die Arbeit nennt 68 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Vancouver Prostate Centre, Vancouver, BC V6H 3Z6, Canada.
- Aranda Pharma Ltd., 70210 Kuopio, Finland.
Zitieren
APA
Nouruzi, S., Johnson, F., Kumar, S., Sivak, O., Tabrizian, N., Koistinaho, M., Muona, A., & Zoubeidi, A. (2024). Targeting adenocarcinoma and enzalutamide‑resistant prostate cancer using the novel anti‑androgen inhibitor ADA‑308. Oncology Reports. https://doi.org/10.3892/or.2024.8791
Vancouver
Nouruzi S, Johnson F, Kumar S, Sivak O, Tabrizian N, Koistinaho M, et al. Targeting adenocarcinoma and enzalutamide‑resistant prostate cancer using the novel anti‑androgen inhibitor ADA‑308. Oncology Reports. 2024. doi:10.3892/or.2024.8791
BibTeX
@article{Nouruzi2024,
author = {Nouruzi, Shaghayegh and Johnson, Fraser and Kumar, Sahil and Sivak, Olena and Tabrizian, Nakisa and Koistinaho, Milla and Muona, Anu and Zoubeidi, Amina},
title = {Targeting adenocarcinoma and enzalutamide‑resistant prostate cancer using the novel anti‑androgen inhibitor ADA‑308},
journal = {Oncology Reports},
year = {2024},
doi = {10.3892/or.2024.8791}
}
EUVIMED